Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NSAIDs May Lower Breast Cancer Recurrence Rate

August 14, 2014 3:30 pm | News | Comments

Recurrence of hormone-related breast cancer was cut by half in overweight and obese women who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), according to new data. Read more...            

TOPICS:

Amgen Multiple Myeloma Drug Misses Phase 3 Endpoint

August 14, 2014 3:24 pm | News | Comments

Amgen and its subsidiary Onyx Pharmaceuticals Inc. announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival (OS). Read more...                   

TOPICS:

Allergan Buys Bladder Treatment Program from TARIS Biomedical

August 14, 2014 3:17 pm | News | Comments

Allergan and TARIS Holdings announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's lead program, LiRIS, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Read more...

TOPICS:
Advertisement

Potential Drug Therapy for Kidney Stones Identified

August 14, 2014 3:10 pm | News | Comments

Anyone who has suffered from kidney stones is keenly aware of the lack of drugs to treat the condition, which often causes excruciating pain. Now, a new mouse study suggests that a class of drugs approved to treat leukemia and epilepsy also may be effective against kidney stones, researchers report. Read more...

TOPICS:

Injection of Modified Bacteria Shrinks Tumors

August 14, 2014 3:00 pm | News | Comments

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report. Read more...              

TOPICS:

Liberia Gets ZMapp, Ponders Who Should Get It

August 14, 2014 2:50 pm | by Jonathan Paye-Layleh and Sarah DiLorenzo | News | Comments

Liberian officials faced a difficult choice Thursday: deciding which handful of Ebola patients will receive an experimental drug that could prove life-saving, ineffective or even harmful. Read more...               

TOPICS:

Breaking News: NewLink Genetics to Test Ebola Vaccine

August 14, 2014 12:48 pm | by Tom Murphy, AP Business Writer | News | Comments

An Iowa drug developer is preparing to test a possible Ebola vaccine in humans, as scientists race to develop ways to prevent or fight a virus that has killed more than 1,000 people in a West African outbreak and for which there is no proven treatment or vaccine. Read more...

TOPICS:

Post-EMA Approval Studies for Agitation Drug Progressing

August 14, 2014 11:08 am | News | Comments

Alexza Pharmaceuticals Inc. provided an update on its European Medicines Agency (EMA) post-approval studies for Adasuve inhalation powder, pre-dispensed (loxapine), of which two have been completed and the data submitted to the EMA. Read more...

TOPICS:
Advertisement

iBio, Kanematsu Chemicals Partner on Biologics Development, Production

August 14, 2014 11:02 am | News | Comments

iBio Inc. and Kanematsu Chemicals Corp., part of Kanematsu Corp., have entered into a collaboration agreement under which Kanematsu Chemicals Corp. will market the novel iBioLaunch platform in Japan, which commands 9% of global biologics sales (led only by the U.S. and the EU). Read more...

TOPICS:

Severe Asthma Drug Advances to Phase 3

August 14, 2014 10:47 am | News | Comments

AstraZeneca announced the start of the Phase 3 program for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm. Read more...

TOPICS:

NEJM Publishes Positive Data for High-Dose Flu Vaccine

August 14, 2014 10:42 am | News | Comments

Sanofi Pasteur announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose (Influenza Vaccine) was more efficacious in preventing influenza in adults 65 years of age and older compared to standard-dose Fluzone vaccine. Read more...

TOPICS:

FDA Approves Merck’s Insomnia Drug

August 14, 2014 10:35 am | by Matthew Perrone, AP Health Writer | News | Comments

Merck & Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep by temporarily blocking chemicals known as orexins that control the sleep cycle and can keep people awake at night. Read more...

TOPICS:

Study Reveals How Ebola Blocks Immune System

August 14, 2014 10:28 am | News | Comments

The Ebola virus, in the midst of its biggest outbreak on record, is a master at evading the body’s immune system, but researchers at Washington University School of Medicine in St. Louis and elsewhere have learned one way the virus dodges the body’s antiviral defenses, providing important insight that could lead to new therapies. Read more...

TOPICS:

BDSI, Endo Pursue Pain Drug after FDA Meeting

August 13, 2014 2:50 pm | News | Comments

BioDelivery Sciences International and Endo Pharmaceuticals engaged in a positive pre-New Drug Application (NDA) meeting with the FDA regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Read more...

TOPICS:

Rigel Dry Eye Drug Misses Endpoints in Phase 2

August 13, 2014 2:42 pm | News | Comments

Rigel Pharmaceuticals Inc. announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. Read more…         

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading